Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
The Journal of Biological Chemistry
|
April 18, 2003
BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit
Miriam Benezra, Nathalie Chevallier, Debra J Morrison, et al.
Cancer Biology & Therapy
|
November 15, 2006
Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling
Adda Grimberg, Carrie M Coleman, Zonggao Shi, et al.
Human Gene Therapy
|
August 22, 2022
Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies
Jeffrey S Moffit, Diann L Blanset, Jessica L Lynch, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
October 26, 2011
Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice
Meghan M Flaherty, Timothy K MacLachlan, Misty Troutt, et al.
Mabs
|
May 6, 2017
Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use
Fiona Sewell, Kathryn Chapman, Jessica Couch, et al.
Molecular Therapy. Methods & Clinical Development
|
January 24, 2018
Nonclinical Safety Evaluation of scAAV8-<i>RLBP1</i> for Treatment of <i>RLBP1</i> Retinitis Pigmentosa
Timothy K MacLachlan, Mark N Milton, Oliver Turner, et al.
Regulatory Toxicology and Pharmacology : RTP
|
November 21, 2020
Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies
Timothy K MacLachlan, Sven Kronenberg, Nikki Marshall, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 2, 2010
Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration
Timothy K Maclachlan, Michael Lukason, Margaret Collins, et al.
Regulatory Toxicology and Pharmacology : RTP
|
March 22, 2017
Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics
Christina L Zuch de Zafra, Vito G Sasseville, Steven Matsumoto, et al.
Regulatory Toxicology and Pharmacology : RTP
|
April 23, 2017
Corrigendum to "Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics" [Regul. Toxicol. Pharmacol. (2017) 221-230]
Christina L Zuch de Zafra, Vito G Sasseville, Steven Matsumoto, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
The Journal of Biological Chemistry
|
April 18, 2003
BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit
Miriam Benezra, Nathalie Chevallier, Debra J Morrison, et al.
Cancer Biology & Therapy
|
November 15, 2006
Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling
Adda Grimberg, Carrie M Coleman, Zonggao Shi, et al.
Human Gene Therapy
|
August 22, 2022
Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies
Jeffrey S Moffit, Diann L Blanset, Jessica L Lynch, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
October 26, 2011
Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice
Meghan M Flaherty, Timothy K MacLachlan, Misty Troutt, et al.
Mabs
|
May 6, 2017
Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use
Fiona Sewell, Kathryn Chapman, Jessica Couch, et al.
Molecular Therapy. Methods & Clinical Development
|
January 24, 2018
Nonclinical Safety Evaluation of scAAV8-<i>RLBP1</i> for Treatment of <i>RLBP1</i> Retinitis Pigmentosa
Timothy K MacLachlan, Mark N Milton, Oliver Turner, et al.
Regulatory Toxicology and Pharmacology : RTP
|
November 21, 2020
Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies
Timothy K MacLachlan, Sven Kronenberg, Nikki Marshall, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 2, 2010
Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration
Timothy K Maclachlan, Michael Lukason, Margaret Collins, et al.
Regulatory Toxicology and Pharmacology : RTP
|
March 22, 2017
Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics
Christina L Zuch de Zafra, Vito G Sasseville, Steven Matsumoto, et al.
Regulatory Toxicology and Pharmacology : RTP
|
April 23, 2017
Corrigendum to "Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics" [Regul. Toxicol. Pharmacol. (2017) 221-230]
Christina L Zuch de Zafra, Vito G Sasseville, Steven Matsumoto, et al.
Page
of 3